摘要
氯吡格雷对血小板的抑制作用具有个体差异性。氯吡格雷抵抗是指那些接受了标准的抗血小板治疗的病人仍然发生不良的心血管事件。导致氯吡格雷抵抗的原因是多方面的,主要有P2Y12受体及CYP3A的基因多态性、药物吸收及活性代谢物清除的个体差异、血小板高反应性等。目前对氯吡格雷抵抗仍然缺乏统一的标准,正确认识、发现、解决氯吡格雷抵抗需要更深入的研究。
Clopidogrel-induced platelet inhibition is patient-specific. Its antiplatelet effect is not uniform in all patients. Clopidogrel resistance illustrates that cardiovascular events still occur in those patients who are taking standard-dose clopidogrel therapy. There is currently no consensus as to what exactly constitutes clopidogrel resistance. The interpatient variability in clopidogrel response is muhifactorial. The possible mechanisms include genetic polymorphisms of the P2Y12 receptor and of the CYP3As, variable absorption of the prodrug, or clearance of the active metabolite, or platelet high sensitivity. Further study is needed of clopidogrel resistance.
出处
《心血管病学进展》
CAS
2007年第4期550-554,共5页
Advances in Cardiovascular Diseases
关键词
氯吡格雷
药物抵抗
血小板聚集
clopidogrel
drug resistance
platelet aggregation
